A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics. Our lead marketed products, listed below, are approved in countries around the world to improve patient care. •Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by FDA in July 2020, and launched in the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 4.3B | 4.3B | 4.1B | 3.8B | 3.7B | 3.1B |
| Net Income | -356M | -356M | 560M | 415M | -224M | -330M |
| EPS | $-5.84 | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
| Free Cash Flow | 1.3B | 1.3B | 1.4B | 1.1B | 1.2B | 751M |
| ROIC | -4.1% | -3.8% | 12.8% | 8.6% | -0.8% | 1.8% |
| Gross Margin | 51.6% | 51.6% | 74.2% | 73.9% | 54.8% | 72.5% |
| Debt/Equity | 1.26 | 1.26 | 1.51 | 1.55 | 1.88 | 1.55 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -430M | -430M | 717M | 579M | -66M | 170M |
| Operating Margin | -10.1% | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% |
| ROE | -8.2% | -8.5% | 14.3% | 12.2% | -6.4% | -8.6% |
| Shares Outstanding | 61M | 61M | 65M | 68M | 63M | 60M |
Jazz Pharmaceuticals plc passes 3 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 9.3x vs a median of 9.9x. The company's 5-year average ROIC is 3.7% with a gross margin of 65.4%. Total shareholder yield (buybacks) is 1.0%. At current prices, the estimated annualized return to fair value is +8.6%.
Jazz Pharmaceuticals plc (JAZZ) has a 5-year average return on invested capital (ROIC) of 3.7%. This is below average and may indicate limited pricing power.
Jazz Pharmaceuticals plc (JAZZ) has a market capitalization of $11.9B. It is classified as a large-cap stock.
Jazz Pharmaceuticals plc (JAZZ) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.05%.
Jazz Pharmaceuticals plc (JAZZ) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Jazz Pharmaceuticals plc (JAZZ) reported annual revenue of $4.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
Jazz Pharmaceuticals plc (JAZZ) has a net profit margin of -8.3%. The company is currently unprofitable.
Jazz Pharmaceuticals plc (JAZZ) generated $1.3 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Jazz Pharmaceuticals plc (JAZZ) has a debt-to-equity ratio of 1.26. This indicates moderate leverage.
Jazz Pharmaceuticals plc (JAZZ) reported earnings per share (EPS) of $-5.84 in its most recent fiscal year.
Jazz Pharmaceuticals plc (JAZZ) has a return on equity (ROE) of -8.5%. A negative ROE may indicate losses or negative equity.
Jazz Pharmaceuticals plc (JAZZ) has a 5-year average gross margin of 65.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for Jazz Pharmaceuticals plc (JAZZ), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Jazz Pharmaceuticals plc (JAZZ) has a book value per share of $70.81, based on its most recent annual SEC filing.